FibroGen Income Statement 2025-2011 | FGEN

Brief overview of profit and loss at FibroGen

The figures are compared over a five-year interval. Revenue at FibroGen moved from 176 million dollars in 2020 to 6.4 million dollars in 2025. The five-year change reached −96.3%, while CAGR stood at −48.4%. The business finished the period with a smaller revenue base.

Gross profit was $167 million at the start and $5.9 million at the end of the period (−96.5%). Revenue and direct costs changed at similar rates. Gross profit as a share of revenue changed from 95% to 91.4%. The margin decline reflects a less favorable sales-and-cost structure.

EBITDA changed from −$180 million to −$45.2 million (+74.9%). EBITDA expanded faster than the top line. EBITDA margin was −102.2% at the start and −701.6% at the end. Cost pressure reduced operating profitability.

The final result was −$189 million initially and $183 million in the final year. The business moved out of a loss and ended the period with a profit.

Overall conclusion

Signs of deterioration dominate the five-year picture. The positive side is supported by improving net profitability. The most visible risks are weak sales momentum, limited operating profitability and pressure from direct costs. Investors should continue to monitor margins, costs, and earnings quality.